reports
- Sean Conroy
InMed Pharmaceuticals - INM-755 trial full enrollment expected this qu...
InMed Pharmaceuticals recently announced that the first human clinical trial (755-101-HV) of its lead program, INM-755 for the treatment of epidermolysis bullosa (EB), is currently around 50% enrolled with full enrollment expected this quarter and data in H220. This trial is testing two strengths of INM-755 cream on the intact skin of 22 healthy volunteers. The company expects to file a clinical trial application (CTA) for a second trial (755-102-HV) this quarter with initiation in Q220. This up...
- Sean Conroy
InMed Pharmaceuticals - Developing cannabinol (CBN)
InMed has announced that the cannabinoid that is the basis for both its epidermolysis bullosa (EB) and glaucoma programs is cannabinol (CBN). This puts InMed in an attractive position (especially from an intellectual property perspective) as other medical cannabis programs are focused on either tetrahydrocannabinol (THC) and/or cannabidiol (CBD) for a variety of indications. Importantly, from a regulatory perspective, CBN is believed to have either slight or no psychoactivity, but it does have a...
- Sean Conroy
InMed Pharmaceuticals - CTA filed on schedule
InMed Pharmaceuticals recently announced that it filed a Clinical Trial Application (CTA) in the Netherlands for INM-755, which is being developed for epidermolysis bullosa (EB). Approval of the CTA is expected around the end of November with the first trial (755-101-HV) expected to begin in December. This trial will test two strengths of INM-755 cream on the intact skin of 22 healthy volunteers. Following the completion of this trial, the company expects to initiate trial 755-102-HV, which woul...
- Sean Conroy
InMed Pharmaceuticals - INM-755 getting closer to the clinic
InMed recently reported results for FY19 and is on track for INM-755 for epidermolysis bullosa (EB) to be in the clinic by the end of 2019. The Phase I programme will consist of two trials, one in healthy volunteers with intact skin and the other in healthy volunteers with small wounds. A Phase I/II trial in EB patients is expected to begin in Q121. In glaucoma, the company has switched its lead candidate to INM-088, which has some specific advantages to the former lead, INM-085. Advanced precli...
- Maxim Jacobs
InMed Pharmaceuticals - Executive Interview
In this video, Eric Adams, chief executive officer of InMed Pharmaceuticals, provides an overview of InMed’s differentiated biosynthesis platform and its therapeutic pipeline of cannabinoids. InMed Pharmaceuticals (TSX: IN) is a Canada-based biopharmaceutical company focused on manufacturing and developing cannabinoids. Its biosynthesis platform has the potential to produce cannabinoids at a lower cost and with improved purity compared to currently used methods. The company is also developing ...
- Maxim Jacobs
InMed Pharmaceuticals - Fiscal Q319 results
InMed recently reported results for the third quarter of FY19 and is on track to be in the clinic to treat epidermolysis bullosa (EB) in the second half of this year (consistent with prior guidance for a CTA filing in H219 with entrance into clinic by year-end 2019). In March, it announced that instead of developing a combination cannabinoid product for EB, it would go with a single agent (INM-755) as it discovered in its testing that by increasing the dose of one of the components, efficacy was...
- Maxim Jacobs
InMed Pharmaceuticals - Entering the clinic by the end of the year
InMed recently reported results for the second quarter of FY19 and is on track to bring INM-750 for epidermolysis bullosa (EB) into the clinic by the end of the year. The company recently completed two topical seven-day dose-ranging studies in pigs; the trials evaluated skin irritation, pharmacokinetics, histology and skin/drug concentrations and InMed is on the verge of selecting the contract manufacturing organization that will produce the topical cream necessary for the Phase I trial. Progres...
- Maxim Jacobs
InMed Pharmaceuticals - Biosynthesis and INM-750 Progress on Track
InMed recently reported results for the first quarter of FY19 and continues to make solid progress in bringing INM-750 for epidermolysis bullosa (EB) into the clinic by H219. So far, its selected formulation has demonstrated good drug penetration as a topical formulation, a clean safety profile and that each of the two cannabinoid components plays an important and independent role in combating EB, which is an especially important finding from a regulatory point of view for any combination produc...
- Maxim Jacobs
InMed Pharmaceuticals - Progressing their programs
InMed continues to make progress on its biosynthesis platform, optimizing the genes that lead E. coli to express the cannabinoids and scaling up the fermentation process, both crucial steps needed to achieve commercial scale to address the market. InMed is also optimizing the formulation for INM-750 for epidermolysis bullosa (EB). A final formulation is expected by the end of 2018. The company is also conducting pharmacology, toxicology and other pre-clinical studies in preparation for detailed...
InMed Pharmaceuticals announces increase in Bought Deal offering to $1...
InMed Pharmaceuticals announces increase in Bought Deal offering to $13 million NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 12, 2018 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (TSX:IN) (“InMed” or the “Company”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to purchase, as underwriter, 14,444,560 units of the Company (the “Units”), on a “bought deal” basis pursuant to the filing of a shelf prospectus sup...
InMed Pharmaceuticals Announces $10 Million Bought Deal
InMed Pharmaceuticals Announces $10 Million Bought Deal NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, B.C., June 12, 2018 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (TSX:IN) (“InMed” or the “Company”) is pleased to announce that it has entered into a letter of engagement with Eight Capital, as underwriter, under which Eight Capital has agreed to purchase 11,111,200 units of the Company (the “Units”), on a “bought deal” basis pursuant to the filing of a shelf prospectus supplement, subject to all required regulatory appr...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.